Use our Search box (top right) and you’ll find we’ve written quite a bit about Abyrx over the past year, most recently in January when the company announced it had entered the soft tissue hemostasis market with a commercial deal with Chinese company Haibo Biotechnology Institute. Now the specialty biosurgical products outfit has partnered with SurgiCor, LLC to significantly expand the distribution of its hemostatic bone putty products (AHBP™, Hemasorb™, Hemasorb Apply™, and Hemasorb Plus™) to orthopedic and spine surgeries throughout the United States.
Under the terms of the newly announced agreement, Abyrx says SurgiCor will represent its products in a regional territory and will be responsible for aggregating additional orthopedic and spine distributors throughout the United States. The companies will use the Kairuku™ Platform to organize a variable commissioning structure for SurgiCor and its affiliate distribution representatives and to track product utilization at the point-of-care to ensure accurate and timely reporting of sales and compensation. Kairuku should enable seamless integration of SurgiCor’s representatives and their affiliate partners into Abyrx’s existing distribution network, which currently comprises several hundred cardiac, craniomaxillofacial, and spine representatives.
Founded by Jay Lawson, former President of Stryker® Corporation’s spinal surgery division, and Dean Short, an orthopedic industry veteran with significant general management, sales, and supply chain experience, SurgiCor is one of the country’s largest orthopedic and spine distributors with a national alliance network of over 500 product representatives who service thousands of surgical procedures each week.
Abyrx will maintain responsibility for its own product training and payment of compensation owed to SurgiCor and its partners.
Jay Lawson, SurgiCor’s Co-Founder and Principal, stated, “SurgiCor’s alignment with Abyrx and Kairuku is consistent with our mission to help companies lead their national launch of clinically relevant products to underserved markets and to work with innovative professionals who share our passion for advancing patient care. Abyrx has the most comprehensive product offering in the bone hemostasis marketplace and we believe its pipeline products have breakout potential to significantly improve patient outcomes and help reduce the cost of care.”
“The current frictional dynamics that exist for new product launches to hospitals, particularly within the biosurgical products marketplace, required us to rethink the traditional distribution model and create new solutions to enable Abyrx to access and service operating rooms across surgical specialties,” said John J. Pacifico, President and Chief Executive Officer of Abyrx, Inc. “Abyrx’s partnership with SurgiCor and our use of the Kairuku Platform will enable us to quickly aggregate orthopedic and spine distributors throughout the United States and drive widespread adoption of Abyrx’s hemostatic bone putties and pipeline products in millions of surgical procedures performed each year.”
Source: Abyrx, Inc., PR Newswire